Michael Goodman to Risk Assessment
This is a "connection" page, showing publications Michael Goodman has written about Risk Assessment.
Connection Strength
0.055
-
DeSimone MS, Goodman M, Pehlivanoglu B, Memis B, Balci S, Roa JC, Jang KT, Jang JY, Hong SM, Lee K, Kim H, Choi HJ, Muraki T, Araya JC, Bellolio E, Sarmiento JM, Maithel SK, Losada HF, Basturk O, Reid MD, Koshiol J, Adsay V. T2 gallbladder cancer shows substantial survival variation between continents and this is not due to histopathologic criteria or pathologic sampling differences. Virchows Arch. 2021 May; 478(5):875-884.
Score: 0.031
-
Naik KB, Liu Y, Goodman M, Gillespie TW, Pickens A, Force SD, Steuer CE, Owonikoko TK, Ramalingam SS, Higgins K, Beitler JJ, Shin DM, Willingham FF, El-Rayes B, Landry JC, Fernandez FG, Saba NF. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. Cancer. 2017 Sep 15; 123(18):3476-3485.
Score: 0.024